|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM52 |
Gene summary for TRIM52 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM52 | Gene ID | 84851 |
| Gene name | tripartite motif containing 52 | |
| Gene Alias | RNF102 | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | L0CQ38 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84851 | TRIM52 | S43 | Human | Liver | Cirrhotic | 2.05e-03 | -1.02e-01 | -0.0187 |
| 84851 | TRIM52 | HCC1_Meng | Human | Liver | HCC | 2.22e-34 | -3.70e-02 | 0.0246 |
| 84851 | TRIM52 | HCC2_Meng | Human | Liver | HCC | 1.51e-08 | 7.43e-02 | 0.0107 |
| 84851 | TRIM52 | HCC1 | Human | Liver | HCC | 7.90e-03 | 2.46e+00 | 0.5336 |
| 84851 | TRIM52 | HCC2 | Human | Liver | HCC | 1.55e-09 | 1.59e+00 | 0.5341 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00072494 | Liver | Cirrhotic | I-kappaB kinase/NF-kappaB signaling | 108/4634 | 281/18723 | 2.21e-07 | 5.64e-06 | 108 |
| GO:00431225 | Liver | Cirrhotic | regulation of I-kappaB kinase/NF-kappaB signaling | 95/4634 | 249/18723 | 1.68e-06 | 3.22e-05 | 95 |
| GO:00096155 | Liver | Cirrhotic | response to virus | 126/4634 | 367/18723 | 2.10e-05 | 2.77e-04 | 126 |
| GO:00431234 | Liver | Cirrhotic | positive regulation of I-kappaB kinase/NF-kappaB signaling | 71/4634 | 186/18723 | 3.20e-05 | 3.97e-04 | 71 |
| GO:0051607 | Liver | Cirrhotic | defense response to virus | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
| GO:0140546 | Liver | Cirrhotic | defense response to symbiont | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
| GO:004312312 | Liver | HCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 108/7958 | 186/18723 | 1.28e-05 | 1.43e-04 | 108 |
| GO:004312212 | Liver | HCC | regulation of I-kappaB kinase/NF-kappaB signaling | 138/7958 | 249/18723 | 2.47e-05 | 2.58e-04 | 138 |
| GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
| GO:00510913 | Liver | HCC | positive regulation of DNA-binding transcription factor activity | 131/7958 | 260/18723 | 5.98e-03 | 2.45e-02 | 131 |
| GO:00518654 | Liver | HCC | protein autoubiquitination | 42/7958 | 73/18723 | 6.78e-03 | 2.73e-02 | 42 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM52 | SNV | Missense_Mutation | novel | c.577N>A | p.Arg193Ser | p.R193S | Q96A61 | protein_coding | deleterious(0) | possibly_damaging(0.519) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| TRIM52 | SNV | Missense_Mutation | c.682T>G | p.Phe228Val | p.F228V | Q96A61 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| TRIM52 | insertion | Frame_Shift_Ins | novel | c.262_263insTGCCTAAAATTTATGCTGAATCTTTATCA | p.Arg88LeufsTer34 | p.R88Lfs*34 | Q96A61 | protein_coding | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TRIM52 | insertion | Frame_Shift_Ins | novel | c.399_400insCACAAACAGCACAGCGTGCTGCCTTTGGAGGAGG | p.Tyr134HisfsTer20 | p.Y134Hfs*20 | Q96A61 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| TRIM52 | deletion | Frame_Shift_Del | novel | c.244delN | p.Ile82PhefsTer30 | p.I82Ffs*30 | Q96A61 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TRIM52 | SNV | Missense_Mutation | c.248N>A | p.Arg83Gln | p.R83Q | Q96A61 | protein_coding | deleterious(0.02) | possibly_damaging(0.457) | TCGA-EK-A3GM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM52 | SNV | Missense_Mutation | c.779T>C | p.Val260Ala | p.V260A | Q96A61 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM52 | SNV | Missense_Mutation | c.529C>A | p.Leu177Ile | p.L177I | Q96A61 | protein_coding | tolerated(0.4) | benign(0.029) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM52 | SNV | Missense_Mutation | novel | c.762C>A | p.Ser254Arg | p.S254R | Q96A61 | protein_coding | tolerated(0.06) | possibly_damaging(0.787) | TCGA-AA-A02J-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| TRIM52 | SNV | Missense_Mutation | c.377A>G | p.Glu126Gly | p.E126G | Q96A61 | protein_coding | deleterious(0) | benign(0.109) | TCGA-AA-A02J-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |